- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Legal & General Group Plc Increases Stake in Bristol Myers Squibb
Institutional investor boosts ownership in biopharmaceutical company
Published on Mar. 10, 2026
Got story updates? Submit your updates here. ›
Legal & General Group Plc, a major institutional investor, has increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 8.4% in the third quarter, according to a recent SEC filing. The firm now owns approximately 17 million shares, or 0.84% of the biopharmaceutical company's stock, valued at over $770 million.
Why it matters
This move by Legal & General Group Plc, one of the world's largest asset managers, signals continued confidence in Bristol Myers Squibb's long-term growth prospects. As a major shareholder, Legal & General's increased investment could indicate positive sentiment around the company's drug pipeline, recent acquisitions, and overall strategic direction.
The details
According to the filing, Legal & General Group Plc purchased an additional 1.3 million shares of Bristol Myers Squibb in the third quarter, bringing its total ownership to 17,075,743 shares. This makes the firm one of the largest institutional investors in the biopharmaceutical company. Bristol Myers Squibb's stock has seen strong performance in recent quarters, driven by the success of its cancer immunotherapy drugs and other pipeline advancements.
- Legal & General Group Plc increased its stake in Bristol Myers Squibb during the third quarter of 2026.
The players
Legal & General Group Plc
A major global asset management firm headquartered in the United Kingdom, with over $1.5 trillion in assets under management.
Bristol Myers Squibb Company
A leading biopharmaceutical company focused on developing innovative medicines for serious diseases, including cancer, cardiovascular, immunology and specialty conditions.
The takeaway
Legal & General Group's increased investment in Bristol Myers Squibb underscores the institutional confidence in the biopharmaceutical company's long-term growth potential. As a major shareholder, Legal & General's move could signal positive market sentiment around Bristol Myers Squibb's pipeline and strategic direction.
